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Orbis Biosciences advances human and animal health pharmaceuticals and 
vaccines by leveraging controlled release platform technologies.  Using Precision 
Particle Fabrication (PPF) technology, Orbis provides desired delivery rates, including 
sustained release, pulsatile delivery for single-shot vaccines, and differentiated delivery 
of novel and generic drugs.  By partnering with pharmaceutical companies, Orbis 
integrates PPF technology into client’s products.  As a proof point, the team formulated 
a single injection, 10-day pain relief drug for pets that tightly maintained constant blood 
levels of the drug. 
Pharmaceutical and biotech companies do not have a robust, affordable, and 
scalable solution for controlled release and delivery of drugs.  Today’s high-cost and 
low-yield solutions for controlling the size and properties of drug particles have led to: 
• Unpredictable release profiles driven by little control over particle size and 
morphology; 
• Batch processes that are extremely costly and difficult to scale; and 
• Undesirable toxicity for localized drug delivery. 
The U.S. market for controlled release is $17BN for human pharmaceuticals and 
$2.5BN for animal health.  Reformulation of an approved drug in a new delivery system 
is significantly less costly than developing a new drug altogether.  This approach 
optimizes product life cycle by extending patent protection by 10-15 years and 
recapturing much of the 60-75% drop in revenue attributable to competition from 
generics. 
In one example, current postoperative pain medicine options for pets provide 
relief for only hours at a time.  Pet owners have a strong willingness to pay, but 
available options are inconvenient (repeatable oral doses) or impractical (repeatable 
visits to the vet).  The market calls for a long-acting drug that is safe, convenient, and 
practical.  Using PPF, Orbis has formulated a 10-day pain relief drug for pets to address 
the U.S. pain relief market. 
PPF technology produces uniform particles or capsules with a narrow size 
distribution and precise control over particle morphology (e.g., porosity or coating 
thickness).  This solution provides an affordable, scalable solution for controlled release 
of active ingredients to: 
• Eliminate the need for multiple administrations and increase patient 
compliance; 
• Reduce side effects by maintaining a safe, effective drug concentration;  
• Establish greater treatment effectiveness and predictability; 
• Protect active ingredients from interacting with one another or irritating the 
stomach; and 
• Taste-masking foul-tasting and -smelling ingredients. 
This development is possible through collaboration of regional organizations 
including:  
Public laboratories 
• The University of Kansas Particle Characterization & Formulation Lab works at 
the interface of medicine and engineering with an emphasis on precisely 
controlling the physical and chemical properties of particles and biomaterials. 
• PharmCATS, a bioanalytical laboratory affiliated with Kansas State University, 
provides bioanalytical services and in vivo studies. 
 
Private companies 
• Orbis Biosciences, Inc. works with pharmaceutical clients to integrate controlled 
release technology into products. 
• Beckloff Associates, Inc., advises the team on the clinical path to obtain FDA 
approval for drugs.  
 
